Albion Financial Group’s Insight Molecular Diagnostics IMDX Stock Holding History

Albion Financial Group’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$26	Hold	7	–	–	﹤0.01%	784
2026 Q2	$42	Hold	7	–	–	﹤0.01%	640
2026 Q1	$23	Hold	7	–	–	﹤0.01%	728
2025 Q4	$53	Hold	7	–	–	﹤0.01%	642
2025 Q3	$24	Hold	7	–	–	﹤0.01%	645
2025 Q2	$22	Hold	7	–	–	﹤0.01%	581
2025 Q1	$22	Hold	7	–	–	﹤0.01%	603
2024 Q4	$17	Hold	7	–	–	﹤0.01%	677
2024 Q3	$20	Hold	7	–	–	﹤0.01%	505
2024 Q2	$21	Hold	7	–	–	﹤0.01%	508
2024 Q1	$21	Hold	7	–	–	﹤0.01%	497
2023 Q4	$18	Hold	7	–	–	﹤0.01%	470
2023 Q3	$22	Sell	7 -1	-13%	-$4	﹤0.01%	473
2023 Q2	$35	Hold	8	–	–	﹤0.01%	465
2023 Q1	$54	Hold	8	–	–	﹤0.01%	439
2022 Q4	$49	Hold	8	–	–	﹤0.01%	478
2022 Q3	$0	Hold	8	–	–	﹤0.01%	533
2022 Q2	$0	Hold	8	–	–	﹤0.01%	594
2022 Q1	$0	Hold	8	–	–	﹤0.01%	645
2021 Q4	$0	Hold	8	–	–	﹤0.01%	668
2021 Q3	$1K	Hold	8	–	–	﹤0.01%	498
2021 Q2	$1K	Buy	+8	New	+$781	﹤0.01%	494
2020 Q4	$0	Buy	+8	New	+$294	﹤0.01%	499

Other funds holding IMDX

Family Office Research Bethesda, Maryland $260M AUM 20.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

Zevenbergen Capital Investments Edmonds, Washington $4.37B AUM 52.9% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

EverSource Wealth Advisors Birmingham, Alabama $3.11B AUM 21.48% 1-Year Est. Return

Transce3nd Kyle, Texas $100M AUM 13.58% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Golden State Equity Partners South Coast Metro, California $1.7B AUM 14.02% 1-Year Est. Return

Albion Financial Group's IMDX Position: Q3 2026 in Review

Albion Financial Group held its Insight Molecular Diagnostics (IMDX) position steady in Q3 2026 at 7 shares worth $26. The position accounts for ﹤0.01% of the portfolio, ranked #784.

Albion Financial Group first reported a position in IMDX in Q4 2020 and has held it in 23 quarters since. The position peaked at $1K in Q3 2021. 14 funds tracked by Wall St. Rank hold IMDX as of Q3 2026.

Albion Financial Group held 7 shares of Insight Molecular Diagnostics worth $26 as of Q3 2026.
Albion Financial Group left its Insight Molecular Diagnostics share count unchanged in Q3 2026.
Insight Molecular Diagnostics made up ﹤0.01% of Albion Financial Group's portfolio in Q3 2026, its #784 holding.
Albion Financial Group first reported a position in Insight Molecular Diagnostics in Q4 2020 and has held it in 23 quarters since.
Albion Financial Group's Insight Molecular Diagnostics position peaked at $1K in Q3 2021.
14 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2026.

Based on Albion Financial Group's 13F filing for Q3 2026, filed 21 Oct 2026.